ATNX Stock Price, Chart, Stats & News

Athenex, Inc.
Save
2.33M
Market cap
–
Current P/E
–
Forward P/E
ATNX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 25.97% |
Operating margin | -68.02% |
Pretax margin | -95.92% |
Net margin | -96.26% |
Effective tax rate | -0.35% |
ROA | -48.50% |
ROE | 21.51% |
D/E | -6.51x |
Interest coverage ratio | -2.71x |
ATNX valuation
P/E | – |
P/S | 0.02x |
P/B | -0.20x |
P/CF | -0.02x |
P/FCF | -0.03x |
P/OCF | -0.02x |
PEG | -0.00x |
EV multiple | 0.06x |
About
Athenex, Inc. is a biopharmaceutical company primarily dedicated to the discovery, advancement, and commercialization of therapeutic agents for oncological conditions. Its operations are structured across three distinct platforms: an Oncology Innovation Platform, a Global Supply Chain Platform, and a Commercial Platform. Among its leading product candidates is the Orascovery series, featuring oral paclitaxel combined with encequidar – an innovative oral formulation.
Similar securities
Based on sector and market capitalization
Report issue











